It remains open as to whether TIL subtypes linked with presumably protumor characteristics, such as PD-1+ TILs and FOXP3+ TILs, are linked with a higher or lower response to chemotherapeutics used in the NST of breast cancer. The gene discussed is FOXP3; the disease is breast carcinoma.